Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology; D001792:Blood Platelets / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D007866:Leg / Q000098:blood supply*; D010974:Platelet Aggregation / Q000187:drug effects*; D010978:Platelet Factor 4 / Q000378:metabolism; D013468:Suloctidil / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology; D013928:Thromboxane A2 / Q000096:biosynthesis; D013988:Ticlopidine; D001620:beta-Thromboglobulin / Q000378:metabolism
D000925:Anticoagulants; D013876:Thiophenes; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D013928:Thromboxane A2; D013988:Ticlopidine; D013468:Suloctidil